Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer

BMC Cancer - Tập 8 Số 1 - 2008
Florian Fritzsche1, Wilko Weichert1, A.-E. Roske1, Volker Gekeler2, Thomas Beckers3, Carsten Stephan4, Klaus Jung4, Katharina Scholman1, Carsten Denkert1, Manfred Dietel1, Glen Kristiansen5
1Institute of Pathology, Charité Universitätsmedizin, Berlin, Germany
2Nycomed GmbH, Konstanz, Germany
3Oncotest GmbH, Freiburg, Germany
4Department of Urology, Charité Universitätsmedizin, Berlin, Germany
5Institute of Surgical Pathology, UniversitätsSpital Zürich, Zurich, Switzerland

Tóm tắt

Abstract Background Enhanced activity of histone deacetylases (HDAC) is associated with more aggressive tumour behaviour and tumour progression in various solid tumours. The over-expression of these proteins and their known functions in malignant neoplasms has led to the development of HDAC inhibitors (HDI) as new anti-neoplastic drugs. However, little is known about HDAC expression in renal cell cancer. Methods We investigated the expression of HDAC 1, 2 and 3 in 106 renal cell carcinomas and corresponding normal renal tissue by immunohistochemistry on tissue micro arrays and correlated expression data with clinico-pathological parameters including patient survival. Results Almost 60% of renal cell carcinomas expressed the HDAC isoforms 1 and 2. In contrast, HDAC 3 was only detected in 13% of all renal tumours, with particular low expression rates in the clear cell subtype. HDAC 3 was significantly higher expressed in pT1/2 tumours in comparison to pT3/4 tumours. Expression of class I HDAC isoforms correlated with each other and with the proliferative activity of the tumours. We found no prognostic value of the expression of any of the HDAC isoforms in this tumour entity. Conclusion Class I HDAC isoforms 1 and 2 are highly expressed in renal cell cancer, while HDAC 3 shows low, histology dependent expression rates. These unexpected differences in the expression patterns suggests alternative regulatory mechanisms of class I HDACs in renal cell cancer and should be taken into account when trials with isoform selective HDI are being planned. Whether HDAC expression in renal cancers is predictive of responsiveness for HDI will have to be tested in further studies.

Từ khóa


Tài liệu tham khảo

Minucci S, Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature reviews. 2006, 6 (1): 38-51. 10.1038/nrc1779.

Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC: Clinical development of histone deacetylase inhibitors as anticancer agents. Annual review of pharmacology and toxicology. 2005, 45: 495-528. 10.1146/annurev.pharmtox.45.120403.095825.

Liu T, Kuljaca S, Tee A, Marshall GM: Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev. 2006, 32 (3): 157-165. 10.1016/j.ctrv.2005.12.006.

Krusche CA, Wulfing P, Kersting C, Vloet A, Bocker W, Kiesel L, Beier HM, Alfer J: Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast cancer research and treatment. 2005, 90 (1): 15-23. 10.1007/s10549-004-1668-2.

Song J, Noh JH, Lee JH, Eun JW, Ahn YM, Kim SY, Lee SH, Park WS, Yoo NJ, Lee JY, Nam SW: Increased expression of histone deacetylase 2 is found in human gastric cancer. Apmis. 2005, 113 (4): 264-268. 10.1111/j.1600-0463.2005.apm_04.x.

Ishihama K, Yamakawa M, Semba S, Takeda H, Kawata S, Kimura S, Kimura W: Expression of HDAC1 and CBP/p300 in human colorectal carcinomas. Journal of clinical pathology. 2007, 60 (11): 1205-1210. 10.1136/jcp.2005.029165.

Weichert W, Roske A, Gekeler V, Beckers T, Ebert MP, Pross M, Dietel M, Denkert C, Rocken C: Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. The lancet oncology. 2008, 9 (2): 139-148. 10.1016/S1470-2045(08)70004-4.

Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M, Kristiansen G: Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. British journal of cancer. 2008, 98 (3): 604-610. 10.1038/sj.bjc.6604199.

Weichert W, Roske A, Niesporek S, Noske A, Buckendahl AC, Dietel M, Gekeler V, Boehm M, Beckers T, Denkert C: Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo. Clin Cancer Res. 2008, 14 (6): 1669-1677. 10.1158/1078-0432.CCR-07-0990.

Atmaca A, Al-Batran SE, Maurer A, Neumann A, Heinzel T, Hentsch B, Schwarz SE, Hovelmann S, Gottlicher M, Knuth A, Jager E: Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. British journal of cancer. 2007, 97 (2): 177-182. 10.1038/sj.bjc.6603851.

Chavez-Blanco A, Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L, Cetina L, Candelaria M, Cantu D, Gonzalez-Fierro A, Garcia-Lopez P, Zambrano P, Perez-Plasencia C, Cabrera G, Trejo-Becerril C, Angeles E, Duenas-Gonzalez A: Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Molecular cancer. 2005, 4 (1): 22-10.1186/1476-4598-4-22.

Marks PA, Breslow R: Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nature biotechnology. 2007, 25 (1): 84-90. 10.1038/nbt1272.

Li LC, Carroll PR, Dahiya R: Epigenetic changes in prostate cancer: implication for diagnosis and treatment. Journal of the National Cancer Institute. 2005, 97 (2): 103-115.

Yoo CB, Jones PA: Epigenetic therapy of cancer: past, present and future. Nature reviews. 2006, 5 (1): 37-50. 10.1038/nrd1930.

Blaheta RA, Cinatl J: Anti-tumor mechanisms of valproate: a novel role for an old drug. Medicinal research reviews. 2002, 22 (5): 492-511. 10.1002/med.10017.

Blaheta RA, Michaelis M, Driever PH, Cinatl J: Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Medicinal research reviews. 2005, 25 (4): 383-397. 10.1002/med.20027.

Richon VM, Zhou X, Rifkind RA, Marks PA: Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Blood cells, molecules & diseases. 2001, 27 (1): 260-264. 10.1006/bcmd.2000.0376.

Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni TB, Salumbides BC, Van Erp K, Schulick R, Pili R: Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clin Cancer Res. 2007, 13 (15 Pt 1): 4538-4546. 10.1158/1078-0432.CCR-07-0014.

VanOosten RL, Earel JK, Griffith TS: Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors. Cancer gene therapy. 2006, 13 (6): 628-632. 10.1038/sj.cgt.7700939.

VanOosten RL, Moore JM, Karacay B, Griffith TS: Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression. Cancer biology & therapy. 2005, 4 (10): 1104-1112.

Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang SM, Harari PM: Modulation of radiation response by histone deacetylase inhibition. International journal of radiation oncology, biology, physics. 2005, 62 (1): 223-229. 10.1016/j.ijrobp.2004.12.088.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA: a cancer journal for clinicians. 2008, 58 (2): 71-96. 10.3322/CA.2007.0010.

Eble JN, Sauter G, Epstein JI, Sesterhenn IA: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. 2004, Lyon: IARC Press

Kristiansen G, Yu Y, Petersen S, Kaufmann O, Schluns K, Dietel M, Petersen I: Overexpression of c-erbB2 protein correlates with disease-stage and chromosomal gain at the c-erbB2 locus in non-small cell lung cancer. Eur J Cancer. 2001, 37 (9): 1089-1095. 10.1016/S0959-8049(01)00096-X.

Noske A, Denkert C, Schober H, Sers C, Zhumabayeva B, Weichert W, Dietel M, Wiechen K: Loss of Gelsolin expression in human ovarian carcinomas. Eur J Cancer. 2005, 41 (3): 461-469. 10.1016/j.ejca.2004.10.025.

Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM: The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer research. 2001, 61 (23): 8492-8497.

Uchida H, Maruyama T, Nagashima T, Asada H, Yoshimura Y: Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin. Endocrinology. 2005, 146 (12): 5365-5373. 10.1210/en.2005-0359.

Uchida H, Maruyama T, Ono M, Ohta K, Kajitani T, Masuda H, Nagashima T, Arase T, Asada H, Yoshimura Y: Histone deacetylase inhibitors stimulate cell migration in human endometrial adenocarcinoma cells through up-regulation of glycodelin. Endocrinology. 2007, 148 (2): 896-902. 10.1210/en.2006-0896.

Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN: Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. The Prostate. 2004, 59 (2): 177-189. 10.1002/pros.20022.

Heerdt BG, Houston MA, Augenlicht LH: Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines. Cancer research. 1994, 54 (12): 3288-3293.

Toh Y, Yamamoto M, Endo K, Ikeda Y, Baba H, Kohnoe S, Yonemasu H, Hachitanda Y, Okamura T, Sugimachi K: Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma. Oncology reports. 2003, 10 (2): 333-338.

Thông tin
Thông tin xuất bản

BMC Cancer

Tập 8 Số 1

Thông tin tác giả